SkinBioTherapeutics - Acquisition of Dermatonics

SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
Acquisition of Dermatonics Limited for initial consideration of
· Established topical dermatological player in skincare/woundcare space
· Provides access to new sales channels for AxisBiotix products and platform for SkinBiotix technology with focus in woundcare
· Immediately revenue and profit accretive, as well as cash flow positive, with additional potential cost synergies
· Revenues of c.
· Brings on board additional operational, sales and regulatory affairs expertise
· Consideration of up to
· Acquisition financed through
The initial consideration is
This acquisition aligns directly with SkinBioTherapeutic's stated strategy to seek accretive inorganic opportunities that provide immediate synergies and accelerated routes to market. In addition, the acquisition provides inorganic revenue growth and reduces losses at a Group level.
Operational and commercial highlights
· Expands SkinBioTherapeutics' product range and customer base
o Established and reputable topical and dermatological company in the skincare/woundcare space
o Products range from heal balm, treatments for warts & verrucas, to dry skin relief
o Dermatonics is ISO13285 registered and products are either Class1 Medical Devices or Cosmetics
o Strong retail customer following and testimonials [Trustpilot 4.9]
· Provides sales platform and new sales channels for SkinBiotix technology and products
o Access to mainstream retailers including Boots and Superdrug, ecommerce (Amazon) and also into specialist podiatry clinics
o Access to new geographies in
o Opportunity for product development in the MediBiotix pillar in woundcare
· Immediately accretive - Dermatonics is currently revenue generating, profitable and cash flow positive, with the additional potential for cost synergies
Further details of Dermatonics are set out below.
Financial highlights
· SkinBioTherapeutics is acquiring 100% of the share capital for up to
o Initial cash consideration of
o Further contingent consideration of up to
· Initial acquisition funding provided through
Further acquisition
The Company is in advanced negotiations and diligence to acquire a second company in a similar sector, with total consideration of less than
"We are delighted to announce our first acquisition as part of our ongoing consolidation strategy in the skincare and hygiene sectors.
"As we have said repeatedly, we have steered a careful course of finding revenue generating and profitable companies that also provide operational synergies to our underlying business. Dermatonics ticks all of these boxes.
"We also gain access to a great customer base including high street retail brands like Boots and Superdrug, plus e-commerce, including Amazon, and more specialist healthcare outlets. Importantly, for the longer term, we gain a platform to back our SkinBiotix™ technology into for our MediBiotix woundcare and skin healing pillar.
"We believe SkinBioTherapeutics and Dermatonics are very complementary as businesses, and we are looking forward to working with the Dermatonics team."
"We have grown Dermatonics over the past 16 years to become a well known and trusted set of brands in the specialist skincare / woundcare market. It makes total sense to us to combine forces with SkinBioTherapeutics who looks at skin care in a similar way to us; we focus on natural ingredients and SBTX focuses on the microbiome. Together, we are stronger, with a broader range of products and an exciting SkinBio technology platform behind them, solid financial resources and scale to enjoy cost efficiencies and synergies. We are excited about the opportunity to become part of the SkinBioTherapeutics team."
-Ends-
Shareholder presentation and Q&A
CEO,
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet SkinBioTherapeutics at the link HERE.
Investors who already follow SkinBioTherapeutics on the Investor Meet Company platform will automatically be invited.
A recording of the presentation will be available shortly afterwards on the SkinBiotherapeutics investor relations section of the website HERE.
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
For more information please contact:
|
SkinBioTherapeutics plc Stuart J. Ashman, CEO
|
Tel: +44 (0) 191 495 7325 |
|
Cavendish Capital Markets Limited
|
Tel: +44 (0) 20 7397 8900 |
|
Instinctif Partners (financial press) |
Tel: +44 (0) 20 7457 2020 |
Additional details about the acquisition of Dermatonics
Overview
As stated in the FY results on
Management was clear that any targets which the Group was interested in purchasing would have to be accretive from a revenue and earnings perspective from day one, and thus reduce the operating cash burn. The overall goal of the Group was to become a cash generating entity within 12-18 months of each acquisition.
The Directors believe that Dermatonics' business and financial performance fulfils all the criteria set by SkinBioTherapeutics, and provides an accretive and synergistic growth opportunity for the Company.
Introduction to Dermatonics
Dermatonics was established in 2008 and specialises in the production of innovative topical and dermatological products in the skincare/woundcare space, with the aim of using natural ingredients wherever possible.
The company's strategy has been to focus its development activities in areas where it identifies room for improvement in products currently available on the market, producing more effective treatments that provide faster results and/or less application.
The business is based in
The business is being sold by its sole owner,
Within the sales and operations team, there are Regulatory Affairs and accounts roles which will be added to in-house capabilities at SkinBioTherapeutics (currently regulatory affairs is outsourced).
Sales roles will remain in place, and there is the potential to push AxisBiotix-Ps through these individuals and channels in time.
Financial performance
For the financial year ended
The acquisition of Dermatonics is expected to be immediately financially accretive through additional revenues and profits.
Product range
The range of products is available at https://www.dermatonics.co.uk.
The business is ISO 13485 registered, and products are either Class 1 Medical Devices or Cosmetics. The products are well proven in the
The prescription range products are also well established and four products are currently listed on the
All manufacturing is outsourced to
Diversified sales routes
Dermatonics has developed five routes to market (channel or distributor) for its products, resulting in diversified revenue streams:
· Prescription (
· Export (e.g.) Alliance Health, AAH, Citysuper,)
· OTC Pharmacy (e.g. Boots, SuperDrug, +well, Cohens chemist, PSUK)
· E-commerce direct to consumer (e.g. Douylin e-commerce, Amazon, Aster DM Healthcare
· Podiatry clinics (e.g. Shuropody)
Geographically, Dermatonics' products are available in the
Academic links
Besides a positive customer following, Dermatonics has strong links with key opinion leaders in the podiatry space who have been long term users and /or have consulted on the creation of new products:
· Professor
·
·
Within the academic and clinical environment, there have been four published studies in connection with Dermatonics's products and technology.
Rationale for acquisition
SkinBioTherapeutics, through its AxisBiotix pillar, aims to develop and market systems of products which aim to heal skin from within (Gut-Skin Axis) and heal from outside (using a range of topicals).
Within the R&D pipeline in SkinBioTherapeutics, are a range of programmes and cost centres which aim to develop topicals using the SkinBioTherapeutics technologies over the coming years as new products / applications are launched, as well as for the current product AxisBiotix-Ps.
SkinBioTherapeutics believes this accretive acquisition fulfils a number of strategic, commercial and operational goals, and is in line with the Company's stated growth strategy.
· Diversifies SkinBioTherapeutics' product portfolio, and sales and distribution channels
Dermatonics is an established and reputable topical and dermatological company in the skincare/woundcaremarket with products classed as either Class 1 Medical Devices or Cosmetics. It markets its products through various sales channels globally and its products are trusted by healthcare professionals, podiatrists and customers.
As well as generating additional revenues from these new products, Dermatonics presents an opportunity to capitalise on these sales channels for existing and new SkinBioTherapeutics products. There is also the opportunity for product development in the MediBiotix Pillar as Dermatonics's creams are also proven to be effective in hard to heal skin/wounds.
· Immediately accretive through revenues generated and cost synergies:
Dermatonics is revenue and profit making, and cash generative, and therefore, would immediately add to SkinBioTherapeutics' financial position.
The acquisition is cash-free and debt-free.
The earn-out has been structured to ensure Dermatonics continues to perform as anticipated. Senior director experience is being retained to ensure a smooth transition as well as performance alignment on deferred consideration.
· Additional senior, regulatory and sales expertise
Dermatonics has a small staff of six including regulatory affairs and bookkeeping. These roles will add to SkinBioTherapeutics' in-house capabilities, in particular, regulatory affairs which is currently outsourced.
The sales staff will be incorporated into the SkinBioTherapeutics team, and as well as being responsible for Dermatonics products, will also be able to take on SkinBioTherapeutics' own products and channels, such as for AxisBiotix-Ps.
At the senior level, the operations manager,
In summary, the Directors of SkinBioTherapeutics anticipate that this acquisition provides the platform for SkinBioTherapeutics to gain access to reputable brands within the skincare/woundcare market in the
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor
The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis.
The Company listed on AIM in
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Group's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE